Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

HEMATOLOGY REPLACEMENT REAGENT CLEARANCE THROUGH "TRUNCATED" 510(K) PROCESS

This article was originally published in The Gray Sheet

Executive Summary

HEMATOLOGY REPLACEMENT REAGENT CLEARANCE THROUGH "TRUNCATED" 510(K) PROCESS recommended by FDA's Hematology and Pathology Devices Advisory Panel at an Aug. 5 meeting in Rockville, Maryland. Asked by FDA about the appropriate clearance mechanism for the devices, the panel suggested an abbreviated 510(k) that would compile some data in summary form. The data would aim to show that the "new reagent satisfies any known performance characteristics," panel member Brian Bull, MD, Loma Linda School of Medicine, California, noted.

Latest Headlines
See All
UsernamePublicRestriction

Register

MT002682

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel